Hemophilia News Today compiled a summary of the 10 most read hemophilia stories of 2024, with links to the individual items.

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

The Wall Street Journal reports how UnitedHealth provided lists of potential, often obscure diagnoses to its doctors and forced them to weigh in on them for each Medicare Advantage patient, in order ...

The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator ...

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

Sangamo Therapeutics' (SGMO) shares were sinking intraday Tuesday after the company said its partner Pfizer (PFE) decided not to proceed with further development of a new gene therapy to treat ...

Hemophilia is an inherited, rare blood disorder in which the patient lacks a protein needed for normal blood clotting ... The prince suffered prolonged bouts of bleeding whenever he cut himself ...

Sangamo Therapeutics (SGMO) stock plunged as Pfizer (PFE) ends collaboration on hemophilia A gene therapy. Find out the ...

Sangamo stock crashes 60.4% as partner Pfizer decides to end collaboration for hemophilia A candidate, giroctocogene fitelparvovec.

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

Increasing Incidence of Hemostasis Disorders: Rising prevalence of hemophilia, thrombophilia, and other blood clotting disorders is driving market growth. Technological Advancements: Continuous ...